146 related articles for article (PubMed ID: 24706728)
1. Strengths, weaknesses, and opportunities of diagnostic breathomics in pleural mesothelioma-a hypothesis.
Lamote K; Nackaerts K; van Meerbeeck JP
Cancer Epidemiol Biomarkers Prev; 2014 Jun; 23(6):898-908. PubMed ID: 24706728
[TBL] [Abstract][Full Text] [Related]
2. Detection of malignant pleural mesothelioma in exhaled breath by multicapillary column/ion mobility spectrometry (MCC/IMS).
Lamote K; Vynck M; Van Cleemput J; Thas O; Nackaerts K; van Meerbeeck JP
J Breath Res; 2016 Sep; 10(4):046001. PubMed ID: 27669062
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma.
Liu H; Wu L; Ji K; Wang W
Tumour Biol; 2015 Sep; 36(10):7375-84. PubMed ID: 26361957
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers and prognostic factors for malignant pleural mesothelioma.
Vigneri P; Martorana F; Manzella L; Stella S
Future Oncol; 2015; 11(24 Suppl):29-33. PubMed ID: 26638920
[TBL] [Abstract][Full Text] [Related]
5. Exhaled breath to screen for malignant pleural mesothelioma: a validation study.
Lamote K; Vynck M; Thas O; Van Cleemput J; Nackaerts K; van Meerbeeck JP
Eur Respir J; 2017 Dec; 50(6):. PubMed ID: 29269578
[TBL] [Abstract][Full Text] [Related]
6. Determining the clinical utility of a breath test for screening an asbestos-exposed population for pleural mesothelioma: baseline results.
Zwijsen K; Schillebeeckx E; Janssens E; Cleemput JV; Richart T; Surmont VF; Nackaerts K; Marcq E; van Meerbeeck JP; Lamote K
J Breath Res; 2023 Sep; 17(4):. PubMed ID: 37683624
[TBL] [Abstract][Full Text] [Related]
7. miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
Cappellesso R; Galasso M; Nicolè L; Dabrilli P; Volinia S; Fassina A
Cancer Cytopathol; 2017 Aug; 125(8):635-643. PubMed ID: 28449331
[TBL] [Abstract][Full Text] [Related]
8. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in malignant pleural mesothelioma.
Davidson B
Hum Pathol; 2015 Jun; 46(6):789-804. PubMed ID: 25824607
[TBL] [Abstract][Full Text] [Related]
10. Chemical characterization of exhaled breath to differentiate between patients with malignant plueral mesothelioma from subjects with similar professional asbestos exposure.
de Gennaro G; Dragonieri S; Longobardi F; Musti M; Stallone G; Trizio L; Tutino M
Anal Bioanal Chem; 2010 Dec; 398(7-8):3043-50. PubMed ID: 20924566
[TBL] [Abstract][Full Text] [Related]
11. Progress of research on microRNAs with diagnostic value in asbestos exposure: A call for method standardization.
Micolucci L; Rippo MR; Olivieri F; Procopio AD
Biosci Trends; 2017 Mar; 11(1):105-109. PubMed ID: 28133000
[TBL] [Abstract][Full Text] [Related]
12. A breath test for malignant mesothelioma using an electronic nose.
Chapman EA; Thomas PS; Stone E; Lewis C; Yates DH
Eur Respir J; 2012 Aug; 40(2):448-54. PubMed ID: 22183490
[TBL] [Abstract][Full Text] [Related]
13. Exhaled Breath Analysis in Diagnosis of Malignant Pleural Mesothelioma: Systematic Review.
Töreyin ZN; Ghosh M; Göksel Ö; Göksel T; Godderis L
Int J Environ Res Public Health; 2020 Feb; 17(3):. PubMed ID: 32050546
[TBL] [Abstract][Full Text] [Related]
14. Serum and pleural fluid biomarkers for mesothelioma.
Creaney J; Robinson BW
Curr Opin Pulm Med; 2009 Jul; 15(4):366-70. PubMed ID: 19417672
[TBL] [Abstract][Full Text] [Related]
15. Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review.
Brusselmans L; Arnouts L; Millevert C; Vandersnickt J; van Meerbeeck JP; Lamote K
Transl Lung Cancer Res; 2018 Oct; 7(5):520-536. PubMed ID: 30450290
[TBL] [Abstract][Full Text] [Related]
16. Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
Ak G; Tada Y; Shimada H; Metintas S; Ito M; Hiroshima K; Tagawa M; Metintas M
BMC Cancer; 2017 Mar; 17(1):212. PubMed ID: 28335760
[TBL] [Abstract][Full Text] [Related]
17. Modulating Immunosuppression in the Intrapleural Space of Malignant Pleural Mesothelioma and Predictive Biomarkers to Guide Treatment Decisions.
Wong RM
J Thorac Oncol; 2016 Oct; 11(10):1602-3. PubMed ID: 27663394
[No Abstract] [Full Text] [Related]
18. Chemokines involved in the early inflammatory response and in pro-tumoral activity in asbestos-exposed workers from an Italian coastal area with territorial clusters of pleural malignant mesothelioma.
Comar M; Zanotta N; Zanconati F; Cortale M; Bonotti A; Cristaudo A; Bovenzi M
Lung Cancer; 2016 Apr; 94():61-7. PubMed ID: 26973208
[TBL] [Abstract][Full Text] [Related]
19. An electronic nose distinguishes exhaled breath of patients with Malignant Pleural Mesothelioma from controls.
Dragonieri S; van der Schee MP; Massaro T; Schiavulli N; Brinkman P; Pinca A; Carratú P; Spanevello A; Resta O; Musti M; Sterk PJ
Lung Cancer; 2012 Mar; 75(3):326-31. PubMed ID: 21924516
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.
Chapel DB; Churg A; Santoni-Rugiu E; Tsujimura T; Hiroshima K; Husain AN
Lung Cancer; 2019 Jan; 127():69-75. PubMed ID: 30642555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
